Rohini Rao on Muck Rack

Rohini Rao

As seen in: Nature, The Indian Express, Financial Express, International Journal of Telemedicine and Applications, Research Journal of Pharmacy and Technology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rohini

Contact Rohini, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Infographic: Study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema

|
By David Brown, Alyson J. Berliner, Rohini Rao
| Nature Verified
Fig. 1 This infographic describes the study design for ELARA (NCT06491914), a phase 3b trial to assess the safety and efficacy of aflibercept 8 mg every 4 weeks followed by a treat-and-extend regimen in patients with neovascular age-related macular degeneration or diabetic macular edema who were previously treated with intravitreal anti-vascular endothelial growth factor agents.
Open in Who Shared Issue with article?
See all 1 licensed articles (2 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified